XY2405 (Anatibant) is a new potent and selective non-peptide antagonist of the Bradykinin B2 receptor in-licensed from Fournier, now a subsidiary of Solvay. Five Phase I clinical trials have evaluated the safety and the pharmacokinetics of the compound in both healthy volunteers and in patients with severe Traumatic Brain Injury (TBI). The compound was shown to be well tolerated. XY2405 has received Fast Track designation and Orphan Drug status in the EU and in the US in January 2004 and April 2005, respectively. TBI is a major cause of disability and death and generates significant economic costs to our society. There is currently no effective therapy available to treat this condition. The combined incidence rate of moderate and severe TBI is estimated to about one million cases per year in the US, Europe and Japan. Severe TBI is often associated with permanent functional and cognitive disorders, learning disabilities and a range of behavioral and emotional problems. The occurrence of TBI is highest among young and elderly people. The leading causes of TBI are motor vehicle accidents, firearms and accidental falls (the leading cause of brain injury in the elderly). TBI is also a major cause of hospitalization in the military. The annual market potential for the first FDA-approved drug treating TBI in the US alone is estimated above $500 million and the worldwide market potential above $2 billion.

Anatibant has been chosen as one of the top 10 most interesting neuroscience projects available for partnering (Windhover's Therapeutic Area Partnership meeting).